Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Bayer
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ryan J. Sullivan, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01078961
First received: March 1, 2010
Last updated: January 2, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)